NASDAQ : EIKN
Eikon Therapeutics, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 5.31 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 287.62M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Selling, General & Admin | 68.40M | 67.11M | 55.81M | 58.48M |
| Research & Development | 270.05M | 247.32M | 204.54M | 207.26M |
| Operating Expenses | 338.45M | 314.43M | 260.34M | 265.74M |
| Operating Income | -338.45M | -314.43M | -260.34M | -265.74M |
| Interest Expense | -837.00K | -837.00K | -31.00K | -39.00K |
| Interest & Investment Income | 17.39M | 15.57M | 16.56M | 23.74M |
| Other Non Operating Income (Expenses) | -63.00K | -32.00K | -3.00K | 42.00K |
| EBT Excluding Unusual Items | -321.96M | -299.73M | -243.81M | -242.00M |
| Merger & Restructuring Charges | 6.00K | -3.29M | ||
| Asset Writedown | -210.00K | -21.23M | ||
| Pretax Income | -322.16M | -324.25M | -243.81M | -242.00M |
| Net Income | -322.16M | -324.25M | -243.81M | -242.00M |
| Preferred Dividends & Other Adjustments | 9.40M | |||
| Net Income to Common | -322.16M | -333.64M | -243.81M | -242.00M |
| Shares Outstanding (Basic) | 23.48M | 2.89M | 2.52M | 2.03M |
| Shares Outstanding (Diluted) | 23.48M | 2.89M | 2.52M | 2.03M |
| EPS (Basic) | -13.72 | -115.29 | -96.76 | -119.43 |
| EPS (Diluted) | -13.72 | -115.29 | -96.76 | -119.43 |
| Free Cash Flow | -259.20M | -235.26M | -219.60M | -219.36M |
| Free Cash Flow Per Share | -11.04 | -81.29 | -87.16 | -108.26 |
| EBITDA | -317.23M | -295.55M | -245.34M | -254.31M |
| D&A For EBITDA | 21.22M | 18.87M | 15.01M | 11.43M |
| EBIT | -338.45M | -314.43M | -260.34M | -265.74M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Cash & Equivalents | 142.61M | 104.90M | 129.18M | 112.78M |
| Short-Term Investments | 388.56M | 231.07M | 90.93M | 317.63M |
| Cash & Short-Term Investments | 531.18M | 335.98M | 220.11M | 430.41M |
| Prepaid Expenses | 15.40M | 12.54M | 7.38M | 6.01M |
| Restricted Cash | 400.00K | 400.00K | 400.00K | |
| Total Current Assets | 546.98M | 348.92M | 227.89M | 436.43M |
| Property, Plant & Equipment | 224.21M | 233.86M | 259.13M | 86.88M |
| Long-Term Deferred Charges | 3.60M | |||
| Other Long-Term Assets | 8.38M | 8.35M | 4.22M | 2.40M |
| Total Assets | 779.57M | 594.73M | 491.24M | 525.71M |
| Accounts Payable | 6.56M | 681.00K | 17.58M | 2.19M |
| Accrued Expenses | 39.29M | 44.16M | 29.16M | 21.00M |
| Current Portion of Leases | 9.45M | 10.03M | 9.31M | 5.05M |
| Other Current Liabilities | 137.00K | 404.00K | 3.21M | |
| Total Current Liabilities | 55.30M | 55.01M | 56.45M | 31.44M |
| Long-Term Leases | 242.77M | 247.29M | 193.15M | 26.69M |
| Other Long-Term Liabilities | 10.00M | 5.35M | 730.00K | |
| Total Liabilities | 313.07M | 312.30M | 254.95M | 58.86M |
| Common Stock | 5.00K | 2.00K | ||
| Additional Paid-In Capital | 1.56B | 41.48M | 33.01M | 19.75M |
| Retained Earnings | -1.09B | -920.51M | -604.94M | -361.13M |
| Total Common Equity | 466.50M | -879.03M | -571.93M | -341.37M |
| Shareholders' Equity | 466.50M | 282.44M | 236.29M | 466.85M |
| Total Liabilities & Equity | 779.57M | 594.73M | 491.24M | 525.71M |
| Total Debt | 252.22M | 257.32M | 202.46M | 31.73M |
| Net Cash (Debt) | 278.96M | 78.66M | 17.65M | 398.68M |
| Net Cash Per Share | 11.88 | 27.18 | 7.01 | 196.75 |
| Filing Date Shares Outstanding | 54.17M | 54.14M | 2.87M | 2.03M |
| Total Common Shares Outstanding | 54.15M | 3.07M | 2.87M | 2.03M |
| Working Capital | 491.68M | 293.91M | 171.44M | 404.99M |
| Book Value Per Share | 8.62 | -286.47 | -199.28 | -168.47 |
| Tangible Book Value | 466.50M | -879.03M | -571.93M | -341.37M |
| Tangible Book Value Per Share | 8.62 | -286.47 | -199.28 | -168.47 |
| Machinery | 59.18M | 58.97M | 54.36M | 49.47M |
| Construction In Progress | 740.00K | 624.00K | 96.86M | 5.42M |
| Leasehold Improvements | 120.59M | 120.59M | 18.61M | 18.34M |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Net Income | -322.16M | -324.25M | -243.81M | -242.00M |
| Depreciation & Amortization | 21.75M | 24.18M | 25.39M | 17.75M |
| Asset Writedown & Restructuring Costs | 210.00K | 21.23M | 35.00M | |
| Loss (Gain) From Sale of Investments | -3.48M | -5.54M | -9.46M | -21.11M |
| Stock-Based Compensation | 14.85M | 18.04M | 12.43M | 9.54M |
| Change in Accounts Payable | 2.64M | -3.81M | 2.95M | 239.00K |
| Change in Other Net Operating Assets | 30.35M | 81.65M | 77.70M | 9.74M |
| Operating Cash Flow | -256.02M | -188.52M | -134.80M | -190.85M |
| Capital Expenditures | -3.18M | -46.74M | -84.80M | -28.51M |
| Investment in Securities | -85.22M | -134.60M | 236.15M | 165.46M |
| Investing Cash Flow | -88.40M | -181.34M | 151.35M | 136.95M |
| Issuance of Common Stock | 350.68M | 1.90M | 244.00K | 402.00K |
| Financing Cash Flow | 350.63M | 352.05M | 244.00K | 105.81M |
| Net Cash Flow | 6.21M | -17.81M | 16.80M | 51.91M |
| Free Cash Flow | -259.20M | -235.26M | -219.60M | -219.36M |
| Free Cash Flow Per Share | -11.04 | -81.29 | -87.16 | -108.26 |
| Levered Free Cash Flow | -208.89M | -190.73M | ||
| Unlevered Free Cash Flow | -208.37M | -190.71M | ||
| Cash Interest Paid | 885.00K | 889.00K | 31.00K | 39.00K |
| Change in Working Capital | 32.99M | 77.83M | 80.65M | 9.98M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Market Capitalization | 307.66M | |||
| Enterprise Value | 28.70M | |||
| Debt / Equity Ratio | 0.54 | 0.91 | 0.86 | 0.07 |
| Net Debt / Equity Ratio | -0.60 | -0.28 | -0.07 | -0.85 |
| Net Debt / EBITDA Ratio | 0.88 | 0.27 | 0.07 | 1.57 |
| Net Debt / FCF Ratio | 1.08 | 0.33 | 0.08 | 1.82 |
| Quick Ratio | 9.61 | 6.11 | 3.90 | 13.69 |
| Current Ratio | 9.89 | 6.34 | 4.04 | 13.88 |
| Return on Equity (ROE) | -125.02% | -69.35% | ||
| Return on Assets (ROA) | -36.19% | -32.00% | ||
| Return on Capital Employed (ROCE) | -46.70% | -58.30% | -59.90% | -53.80% |
| Buyback Yield / Dilution | -831.80% | -14.85% | -24.35% |